Pazopanib in Advanced and Cisplatin-resistant Germ Cell Tumors

NCT01743482 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Germ Cell Tumors
Measurable Disease

Interventions

DRUG: Pazopanib

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborators

[object Object]